User profiles for Alberto Gil-Jimenez
 | Alberto Gil JimenezNetherlands Cancer Institute Verified email at nki.nl Cited by 340 |
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
N van Dijk, A Gil-Jimenez, K Silina, K Hendricksen… - Nature medicine, 2020 - nature.com
Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies has shown
remarkable pathological responses in melanoma 1 and colorectal cancer 2 . In NABUCCO (…
remarkable pathological responses in melanoma 1 and colorectal cancer 2 . In NABUCCO (…
Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer
A Gil-Jimenez, J van Dorp, A Contreras-Sanz… - European urology, 2023 - Elsevier
Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is
recommended for patients with muscle-invasive bladder cancer (MIBC). It has been shown that …
recommended for patients with muscle-invasive bladder cancer (MIBC). It has been shown that …
[HTML][HTML] Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
…, DGJ Robbrecht, A Gil-Jimenez… - Nature …, 2024 - nature.com
Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic urothelial
cancer (mUC), but therapeutic success at the individual patient level varies significantly. …
cancer (mUC), but therapeutic success at the individual patient level varies significantly. …
Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (the PERICLES study): a phase II trial
HM de Vries, TS Rafael, A Gil-Jimenez… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE Patients with advanced penile squamous cell carcinoma have a poor prognosis (21%
2-year overall survival [OS] from diagnosis). We assessed the activity of atezolizumab (…
2-year overall survival [OS] from diagnosis). We assessed the activity of atezolizumab (…
[HTML][HTML] The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer
N Dijk, A Gil-Jimenez, K Silina, ML Montfoort… - Frontiers in …, 2021 - frontiersin.org
Candidate immune biomarkers have been proposed for predicting response to immunotherapy
in urothelial cancer (UC). Yet, these biomarkers are imperfect and lack predictive power. …
in urothelial cancer (UC). Yet, these biomarkers are imperfect and lack predictive power. …
[HTML][HTML] Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors
A Gil-Jimenez, N van Dijk, JL Vos, Y Lubeck… - Nature …, 2024 - nature.com
Immune checkpoint inhibitors (ICI) can achieve remarkable responses in urothelial cancer (UC),
which may depend on tumor microenvironment (TME) characteristics. However, the …
which may depend on tumor microenvironment (TME) characteristics. However, the …
Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO).
N Van Dijk, A Gil Jimenez, K Silina, K Hendricksen… - 2020 - ascopubs.org
5020 Background: Encouraging pathological complete response (pCR) rates were observed
in trials testing neoadjuvant pembrolizumab or atezolizumab in urothelial cancer (UC). In …
in trials testing neoadjuvant pembrolizumab or atezolizumab in urothelial cancer (UC). In …
[PDF][PDF] Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid biopsy assessment of plasma and urine ctDNA using the …
…, N van Dijk, G Jones, A Gil-Jimenez… - Cancer …, 2022 - neogenomics.com
Genigraphics Research Poster Template 44x44 Page 1 Predicting pathological response
after ipilimumab plus nivolumab in stage III urothelial cancer by liquid biopsy assessment of …
after ipilimumab plus nivolumab in stage III urothelial cancer by liquid biopsy assessment of …
T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancer
…, DGJ Robbrecht, A Gil-Jimenez… - bioRxiv, 2022 - biorxiv.org
Immune checkpoint inhibitors (ICIs) improve overall survival in patients with metastatic
urothelial cancer (mUC). To identify predictive markers of response, whole-genome DNA (n=70) …
urothelial cancer (mUC). To identify predictive markers of response, whole-genome DNA (n=70) …
The penile cancer tumor microenvironment and immunotherapy response: Results from the PERICLES trial
TS Rafael, A Gil-Jimenez, HM de Vries, IM Seignette… - Cancer Research, 2024 - AACR
Introduction: The phase II PERICLES trial investigated the efficacy of atezolizumab (anti-PD-L1)
for advanced penile cancer, with or without radiotherapy. As previously published, …
for advanced penile cancer, with or without radiotherapy. As previously published, …